I absolutely would. We tend to choose TNF inhibitors as our first line biologic, largely as a result of therapeutic inertia and a perception that these agents will have an eas...

Treating these manifestations of peripheral SpA is challenging. It is always important to have a baseline assessment of the liver and kidney function as well as other relevant...